SQUIRE, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of versus in

        Z

NCT00981058    Lancet Oncol 2015;16:763-74  



Studied treatment
Control treatment



Patients
Group sizes-9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI0,22,01,0

Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, B├ílint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16:763-74     [PMID: 26045340]   link to pdf   add to Mendeley  

Links

ClinicalTrial.gov record NCT00981058



Registering number NCT00981058 (see trial on clinicaltrials.gov)
Code Name

 

Appears in following systematic reviews: